NCT04706598 2024-07-12
Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment
Fudan University
Phase 1/2 Active not recruiting
Clinical Trials
5 trialsNCT06423170 2024-05-21
A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT05564897 2022-10-04
Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT03827837 2022-07-01
Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT03987698 2020-07-07
Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown